Scientific deep-dive

Semaglutide and Days Spent in Hospital

A prespecified analysis of SELECT found hospital days falling from 176.2 to 157.2 per 100 patient-years. It is a modest number from a randomized trial, which is what makes it trustworthy.

By Nora Bissett · Pricing Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed
5 min read·1 citation

Cardiovascular trials report hazard ratios for events most people will never have. A prespecified analysis of the SELECT trial measured something more recognizable: how much time participants spent in hospital. Semaglutide cut it from 176.2 to 157.2 days per 100 patient-years.[1]

What was measured

SELECT randomized 17,604 people with obesity and established cardiovascular disease but without diabetes. We covered its main result, fewer major cardiovascular events, in the evidence-duration article. This analysis asked a different question of the same trial.

Days hospitalized per 100 patient-years in SELECT.
MeasureSemaglutidePlaceboRate ratio
Any indication157.2176.20.89 (95% CI 0.82–0.98), p=0.01
Serious adverse events137.6153.90.89 (95% CI 0.81–0.98), p=0.02

No heterogeneity appeared across BMI, age or sex subgroups. The reduction was consistent rather than concentrated in one group.[1]

Why days in hospital is a better unit

A hazard ratio for a composite cardiovascular endpoint is hard to feel. Days in hospital is not. It captures severity as well as frequency, since a long admission counts for more than a short one. And it adds up everything that put someone in a bed, not only the events a trial was designed to count.

The cohort had a high rate of hospital admissions to begin with. That is what makes an 11% relative reduction worth stating in days.

It is also the outcome that translates most directly into cost, which is usually argued about separately from clinical benefit. Here one number covers both: time in hospital is expensive for health systems and disruptive for people.

What kind of evidence this is

The analysis was prespecified and exploratory, and the two words mean different things. Prespecified means the analysis was planned before the data were seen, so it is not a result someone went looking for afterward. Exploratory means it was not the endpoint the trial was powered to answer, so it should be read as supportive rather than definitive.

What it has that most hospitalization findings do not is randomization. We have covered several observational studies reporting fewer hospitalizations on these drugs, in people with cancer and in infection risk. Every one of them carries the objection that healthier people get prescribed newer drugs. Randomization removes that objection.

This is a good example of a modest number being more trustworthy than a dramatic one. An 11% relative reduction in hospital days is the size of effect a real drug produces. When observational data show 47%, 78% or 91% mortality reductions, the size itself is the warning, a point we set out in when a hazard ratio is too good.

Frequently Asked Questions

In a prespecified analysis of the SELECT trial, days hospitalized fell from 176.2 to 157.2 per 100 patient-years, a rate ratio of 0.89. Hospitalizations for serious adverse events fell similarly.
Days capture severity as well as frequency, and they add up everything that put someone in a bed, not only the events the trial was designed to count. It is also the number that translates most directly into cost.
It is prespecified but exploratory. It was planned in advance, so it is not a result found by searching, but it was not the endpoint the trial was powered for. What makes it more reliable than similar observational findings is that it comes from a randomized trial.
No heterogeneity was observed across BMI, age or sex. The reduction was consistent rather than concentrated in a subgroup.
In a cohort with a high baseline admission rate, nineteen fewer days per hundred patient-years is a real amount of time. It is also the size of effect real drugs produce, which is part of why it is more believable than the much larger numbers observational studies sometimes report.

References

  1. 1.Nicholls SJ, Ryan DH, Deanfield J, et al. Semaglutide and Hospitalizations in Patients With Obesity and Established Cardiovascular Disease: An Exploratory Analysis of the SELECT Randomized Clinical Trial JAMA Cardiology. 2026. PMID: 41433034.

GLP-1 Drugs and Blood Pressure: How Much It Falls, and What Happens When You Stop

On the FDA labels, systolic blood pressure fell about 4 to 7 points more than placebo on tirzepatide and 3 to 5 on semaglutide. 24-hour monitoring confirmed it, weight loss explained most of it, and in the withdrawal trials much of it came back.

8 min read

GLP-1s and Atrial Fibrillation: Reading a 42% Headline

A meta-analysis of ten trials in 12,651 patients found a 42% lower risk of new atrial fibrillation on semaglutide. None of those trials was designed to measure it, and the absolute numbers were never published.

6 min read

Two Studies, One Comparison, Two Answers

One real-world study found no cardiovascular difference between the two drugs. Another found semaglutide 29% better. Working out why they disagree is more useful than either answer.

6 min read

Semaglutide and Peripheral Artery Disease: The Label, the Options and Coverage

STRIDE showed semaglutide 1 mg improved walking distance in type 2 diabetes with PAD, and Novo Nordisk filed for a US label change in 2025. Ozempic's label still lists no PAD use, but PAD already counts as cardiovascular disease on the Ozempic and Wegovy labels.

7 min read

The Statistic That Asks If Groups Differ

A SOUL secondary analysis found oral semaglutide cutting heart-failure events in people who had heart failure and doing nothing in those who did not. The test of whether that split is real came out at P = .06.

7 min read

The Head-to-Head, and What It Settles

751 adults randomized to tirzepatide or semaglutide, each at maximum tolerated dose, for 72 weeks. Tirzepatide produced 20.2% weight loss against 13.7%, and on several other endpoints the answer runs the other way.

7 min read

Where to get semaglutide online, safely: sellers our editors have checked

These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.

No insurance needed · vetted by our editors

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

9.1

Collective

From $59/mo + membership

Get started →
Read full review →
7.9

Luvo Health

Moving between compounded and brand without changing seller

About this analysis

GLP Watchdog publishes independently. Each seller in our dataset is checked against that seller's own website, and the dataset is updated continuously. Read our full methodology →